FR

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

Retrieved on: 
Monday, March 11, 2024

The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.

Key Points: 
  • The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
  • Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
  • TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
  • Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Strong FY 2023 results, Planisware consistently delivering sustainable profitable growth

Retrieved on: 
Monday, March 11, 2024

At € 6.9 million, 2023 income tax expense reflected an Effective Tax Rate of 14.1%, compared to 15.5% in 2022.

Key Points: 
  • At € 6.9 million, 2023 income tax expense reflected an Effective Tax Rate of 14.1%, compared to 15.5% in 2022.
  • In 2023, adjusted Free Cash Flow reached
    € 43.8 million, up by +64.4% compared to € 26.7 million in 2022, led by Adjusted EBITDA growth.
  • Planisware benefits from a strong cash position, as most of its customers prepay for services, which generates structurally negative working capital requirements.
  • In 2023, Planisware initiated the next phase of its growth strategy through its contemplated IPO on Euronext Paris.

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Retrieved on: 
Monday, March 11, 2024

Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective.

Key Points: 
  • Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective.
  • The Bank of New York Mellon serves as depositary (the “Depositary”) for the Company’s ADS facility.
  • On or about May 28, 2024, the Depositary may elect to sell the underlying ordinary shares.
  • Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold.

Technip Energies publishes 2023 Annual Report

Retrieved on: 
Friday, March 8, 2024

Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the energy transition, today published its 2023 Annual Report.

Key Points: 
  • Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the energy transition, today published its 2023 Annual Report.
  • The Company filed its 2023 Annual Report with the Autoriteit Financiële Markten (AFM) in the Netherlands and the Autorité des marchés financiers (AMF) in France.
  • The 2023 Annual Report is available at:

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Retrieved on: 
Friday, March 8, 2024

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
  • These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com .
  • In addition, the URD is available on the AMF’s website at www.amf-france.org and the Form 10-K is available on the SEC’s website at www.sec.gov .
  • Printed copies of both documents are available, free of charge, at the Company’s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

Crossject gender equality score reaches 96/100 in 2024

Retrieved on: 
Friday, March 8, 2024

Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%.

Key Points: 
  • Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%.
  • The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting policy makers to design more effective gender equality measures.
  • It is assessed by a score from 1 to 100, with 100 meaning full equality between women and men.
  • “We are very proud to reach a record score for gender equality, which is a very important area for Crossject as a maturing public company, in 2024.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 7, 2024

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
  • Published EPITOPE results in the New England Journal of Medicine with an accompanying editorial, entitled, Good News for Toddlers with Peanut Allergy.
  • ET to discuss full year 2023 financial results and provide a business update.
  • The conference call may be accessed by dialing:
    A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor-overview/events .

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Retrieved on: 
Thursday, March 7, 2024

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.

Key Points: 
  • Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
  • Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks.
  • Clinical sites located in the United States operating under central IRB have meanwhile resumed screening and randomization activities.
  • Inventiva anticipates the last patient first visit for the NATiV3 clinical trial in the first half of 2024.

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

Nanobiotix to Present at Upcoming Investor Conferences in March

Retrieved on: 
Wednesday, March 6, 2024

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference.

Key Points: 
  • PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference.
  • Please see below for details on each event.
  • The fireside chats will be webcast live from the events page of the Investors section of the Company’s website.
  • Replays of the webcasts will be available following the events.